# BPC-157 Research Literature — Mechanism, Findings, and Clinical Evidence

> Systematic overview of BPC-157 research: VEGFR2-Akt-eNOS mechanism, eight signaling pathways, twenty preclinical findings cataloged by tissue and species, and three human pilot studies. For research purposes only.

## Mechanism of Action

BPC-157 operates primarily through the VEGFR2-Akt-eNOS signaling axis, driving context-dependent angiogenesis and endothelial nitric oxide production in injured tissue [7, 8, 13]. Unlike a direct growth factor, it functions as a pleiotropic cytoprotection mediator — adjusting nitric oxide levels upward or downward depending on physiological context.

Eight pathways have been cataloged across the published literature:

1. **VEGFR2-Akt-eNOS axis** — Primary angiogenic driver and vascular remodeling signal. Documented in tendon/muscle crush injury and major vessel occlusion models [7, 8].
2. **ERK1/2 phosphorylation** — Endothelial cell proliferation and tube formation. Active in in vitro models and in vivo healing tissue [17].
3. **FAK-paxillin signaling** — Focal adhesion kinase activation driving fibroblast migration and collagen synthesis. Documented in tendon fibroblast models [17].
4. **Growth hormone receptor upregulation** — BPC-157 increased GHR mRNA and protein expression up to 7-fold in rat Achilles tendon fibroblasts at concentrations of 0.1–0.5 μg/mL over three days, potentiating subsequent GH-induced cell proliferation via JAK2 phosphorylation [2].
5. **NF-kB pathway modulation** — Anti-inflammatory signaling; modulated in several GI and tissue injury models.
6. **Dopaminergic and serotonergic system interaction** — Counteraction of dopaminergic disruption and bidirectional serotonin modulation documented in rodent models [9, 10].
7. **NO synthesis modulation** — Context-dependent; pro-NO in vascular occlusion models, anti-NO in pathological hypersensitization states [13].
8. **VEGF and CD34 upregulation** — Confirmed via immunohistochemistry in crush-injured muscle and tendon tissue [7].

Two 2025 reviews confirm this multi-pathway profile through independent literature analysis [17, 20].

## Preclinical Findings by Tissue

**Tendon and ligament:** In surgically transected rat Achilles tendon, BPC-157 at 10 μg/kg and 10 ng/kg intraperitoneal significantly accelerated healing — improving biomechanical load-bearing capacity, Young's modulus of elasticity, and functional gait scores vs. saline controls [1]. Full tendon integrity reestablished by day 14. Medial collateral ligament (MCL) healing was improved through 90 days after surgical transection whether BPC-157 was delivered intraperitoneally, per-orally, or as a topical cream at 1 μg/g [3].

**Muscle:** In a rat muscle crush injury model, 14 days of BPC-157 produced less post-injury hematoma and edema, no leg contracture, superior microscopic recovery, and normalization of creatine kinase, lactate dehydrogenase, and aminotransferase markers versus controls [5]. A 2025 study demonstrated that per-oral BPC-157 at 10 μg/kg and 10 ng/kg in drinking water facilitated complete muscle-to-bone reattachment after total quadriceps surgical detachment — MRI confirmed zero gap at the musculoskeletal junction by day 21–28, versus a 4.1 ± 0.5 mm persistent gap in controls at 90 days [18].

**Bone:** In a rabbit segmental radial bone defect model (0.8 cm defect), BPC-157 at 10 μg/kg delivered locally or intramuscularly produced defect-healing rates comparable to autologous bone marrow graft or cortical bone implantation at 6 weeks [6].

**Wound healing:** Across incisional wounds, excisional wounds, deep burns (20% BSA), diabetic ulcers, and alkali burns in rat and pig models, BPC-157 accelerated re-epithelialization, improved tensile strength, reduced edema, and promoted earlier collagen maturation [4].

**Vascular:** Infrarenal inferior caval vein occlusion, Pringle maneuver ischemia-reperfusion, and Budd-Chiari syndrome consequences were attenuated in rat models at 10 μg/kg via VEGFR2-Akt-eNOS-mediated collateral pathway recruitment [8].

**Neurological:** Counteraction of dopaminergic disruption was documented across multiple models at microgram-to-nanogram doses [9]. BPC-157 simultaneously produced an antidepressant effect in the Porsolt forced swim test exceeding imipramine and resolved full serotonin syndrome [10].

**Angiogenesis specificity:** A 2025 paper documented BPC-157's bidirectional angiogenic capacity: pro-angiogenic in healing tendon and muscle (10 pg–10 μg/kg IP), anti-angiogenic against pathological corneal neovascularization (2 pg/mL–2 μg/mL topical), and reversal of pathological hepatic angiogenesis in cirrhosis models [13].

## Human Pilot Studies

Three human pilot studies have been published as of 2026. Sample sizes are very small; no randomized controlled trials exist.

**Knee pain (2021):** 14 of 16 patients achieved significant pain relief following intra-articular injection of BPC-157 (alone or with TB-500) — an 87.5% response rate at 6–12 month follow-up [16].

**Interstitial cystitis (2024):** 10 of 12 patients with moderate-to-severe interstitial cystitis reported total symptom resolution after a single 10 mg intravesical injection. The remaining 2 reported 80% symptom resolution at 6 weeks post-treatment [15].

**IV safety/pharmacokinetics (2025):** Two participants received BPC-157 IV infusions (10 mg Day 1, 20 mg Day 2 over 1 hour each). No adverse events reported; plasma concentrations returned to baseline within 24 hours [14].

## 2024–2026 Literature Update

**Pharmaceuticals (Basel), 2024 [9, 10]:** Comprehensive review of BPC-157's modulation of dopaminergic, serotonergic, glutamatergic, GABAergic, and NO systems simultaneously. Antidepressant effect exceeded imipramine while simultaneously countering serotonin syndrome.

**Pharmaceutics, 2025 [18]:** Per-oral BPC-157 facilitated complete muscle-to-bone reattachment after total quadriceps surgical detachment; MRI-confirmed zero gap at the musculoskeletal junction by day 21–28.

**HSS Journal, 2025 [17]:** Systematic review of 36 studies identified VEGFR2-Akt-eNOS, ERK1/2, and FAK-paxillin as primary musculoskeletal repair pathways. Three human pilots with no adverse effects.

**Pharmaceuticals (Basel), 2025 [13]:** Bidirectional angiogenic regulation documented. No toxicity at 2 g/kg IV in mice; efficacy at picogram-per-kilogram doses confirmed.

**Pharmaceuticals (Basel), 2025 [20]:** Independent (non-Zagreb group) literature and patent review; confirmed multi-target pharmacology, documented 10 active patents.

**International Journal of Molecular Sciences, 2026 [21]:** Multi-institutional narrative review confirmed preclinical support for tissue repair and pain modulation; identified the gap as human evidence — only three small pilots, no RCTs.

## References

[1] Staresinic M et al. Journal of Orthopaedic Research. 2003;21(6):976-983. DOI: 10.1016/S0736-0266(03)00110-4
[2] Chang CH et al. Molecules. 2014;19(11):19066-19077. DOI: 10.3390/molecules191119066
[3] Cerovecki T et al. Journal of Orthopaedic Research. 2010;28(9):1155-1161. DOI: 10.1002/jor.21107
[4] Seiwerth S et al. Frontiers in Pharmacology. 2021;12:627533. DOI: 10.3389/fphar.2021.627533
[5] Novinscak T et al. Surgery Today. 2008;38(8):716-725. DOI: 10.1007/s00595-007-3706-2
[6] Sebecic B et al. Bone. 1999;24(3):195-202. DOI: 10.1016/s8756-3282(98)00180-x
[7] Brcic L et al. Journal of Physiology and Pharmacology. 2009;60 Suppl 7:191-196. PMID: 20388964
[8] Sikiric P et al. World Journal of Gastroenterology. 2022;28(1):23-45. DOI: 10.3748/wjg.v28.i1.23
[9] Sikiric P et al. Pharmaceuticals (Basel). 2024;17(4):461. DOI: 10.3390/ph17040461
[10] Sikiric P et al. Pharmaceuticals (Basel). 2024;17(4):461. DOI: 10.3390/ph17040461
[13] Sikiric P et al. Pharmaceuticals (Basel). 2025;18(6):928. DOI: 10.3390/ph18060928
[14] Lee E, Burgess K. Alternative Therapies in Health and Medicine. 2025. PMID: 40131143
[15] Lee E, Walker C, Ayadi B. Alternative Therapies in Health and Medicine. 2024.
[16] Lee E, Padgett B. Alternative Therapies in Health and Medicine. 2021. PMID: 33609460
[17] Vasireddi N et al. HSS Journal. 2025. DOI: 10.1177/15563316251355551
[18] Matek D et al. Pharmaceutics. 2025;17(1):119. DOI: 10.3390/pharmaceutics17010119
[20] Jozwiak M et al. Pharmaceuticals (Basel). 2025;18(2):185. DOI: 10.3390/ph18020185
[21] Yuan C et al. International Journal of Molecular Sciences. 2026;27(6):2876. DOI: 10.3390/ijms27062876

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.